CLINICAL OUTCOMES
Protégé GPS Self-expanding Peripheral and Biliary Stent
DURABILITY ILIAC1 was conducted to confirm the safety and effectiveness of primary stenting using the EverFlex™ and Protégé™ GPS™ self-expanding stent systems for the treatment of lesions in the common and external iliac arteries.
- 75 subjects enrolled
- ≥ 50% stenosis, restenosis or occlusion
- Target lesion length ≤ 10 cm
- Target vessel diameter ≥ 4.5 mm and ≤ 11.0 mm
Results of DURABILITY ILIAC study with Protégé GPS Stent:
- 45/75 patients received a Protégé GPS stent
- Nine-month MAE rate of 2.2%
- 2.2% clinically drive TLR
- 0% periprocedural death
- 0% in-hospital MI
- 0% amputation of treated limb
- Nine-month primary patency rate of 97.7%
1Faries, P. Nine-Month Outcomes of DURABILITY ILIAC Trial. VIVA. 2014.